Galapagos - Stock Price History | GLPG

Historical daily share price chart and data for Galapagos since 2021 adjusted for splits. The latest closing stock price for Galapagos as of October 22, 2021 is 50.93.
  • The all-time high Galapagos stock closing price was 274.03 on February 21, 2020.
  • The Galapagos 52-week high stock price is 130.26, which is 155.8% above the current share price.
  • The Galapagos 52-week low stock price is 48.66, which is 4.5% below the current share price.
  • The average Galapagos stock price for the last 52 weeks is 81.81.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Galapagos Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 177.4079 212.0900 274.0300 96.8500 98.9800 -52.14%
2019 142.6299 90.5100 215.8200 89.6100 206.8300 125.45%
2018 102.8985 94.5100 120.2300 87.8100 91.7400 -2.15%
2017 84.5778 65.0200 104.0200 64.3100 93.7600 46.07%
2016 53.7006 60.9600 71.0000 38.0000 64.1900 2.08%
2015 54.0923 50.5000 64.0500 39.0100 62.8800 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.337B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76